SOURCE: World Street Fundamentals

July 06, 2011 09:00 ET

Equity Research on Zalicus Inc. and Regeneron Pharmaceuticals, Inc. - A Healthy Start

HONG KONG--(Marketwire - Jul 6, 2011) - Today, www.WorldStreetFundamentals.com released its industry report highlighting Zalicus Inc. (NASDAQ: ZLCS) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Full fundamental and technical analysis is available at www.WorldStreetFundamentals.com/Reports.php.

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times.

World Street Fundamentals has highlighted Zalicus Inc. as a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain and inflammation. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. On March 1, 2010, the United States Food and Drug Administration, (FDA), approved the New Drug Application (NDA) for Exalgo (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The entire report on Zalicus Inc. (NASDAQ: ZLCS) is available here: www.WorldStreetFundamentals.com/ViewFullReport.245.php.

World Street has highlighted Regeneron Pharmaceuticals, Inc. as a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2010, the Company had one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. The entire report on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is available here: www.WorldStreetFundamentals.com/ViewFullReport.138.php.

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

Contact Information